According to data from the National Health and Nutrition Examination Survey (NHANES), 13.2% of adults used antidepressant medications in the past 30 days between the years of 2015 and 2018. Duloxetine is one of the first-line antidepressants used globally for treating mental health and chronic pain conditions.
Continue reading to learn more about duloxetine's pharmacological profile, common indications, administration guidelines, and strategies for managing side effects and drug interactions. By understanding its therapeutic applications and limitations, clinicians can make informed decisions about managing duloxetine prescriptions to optimize patient care.
[signup]
What Is Duloxetine?
Duloxetine (brand name Cymbalta) is a serotonin and norepinephrine reuptake inhibitor (SNRI). SNRIs are a class of antidepressants that function by inhibiting the reuptake of serotonin and norepinephrine, neurotransmitters involved in the modulation of mood and pain. This dual reuptake inhibition enhances the levels of these neurotransmitters in the central nervous system, contributing to its antidepressant and analgesic (pain-relieving) effects.
Duloxetine was first approved by the Food and Drug Administration (FDA) for treating depression and diabetic-associated neuropathic pain in 2004. Since then, its use expanded to fibromyalgia, generalized anxiety disorder, and chronic musculoskeletal pain. (14)
Duloxetine is available in capsule form in strengths of 20 mg, 30 mg, and 60 mg (13).
Duloxetine's Common Uses
The FDA approves duloxetine to treat certain health conditions. Additionally, your doctor may prescribe duloxetine off-label for other conditions.
Depression
Duloxetine is FDA-approved to treat major depressive disorder (MDD). Common symptoms of depression include:
- Feeling sad most or all of the time
- Feeling irritable or restless
- Losing interest in activities that used to be enjoyable
- Trouble concentrating, making decisions, or remembering things
- Feeling worthless, guilty, or helpless
- Thinking about suicide or self-harm
According to the FDA, the efficacy of duloxetine was established in four short-term studies and one maintenance study involving adult outpatients meeting the diagnostic criteria for MDD. In these trials, duloxetine dosed 60 mg daily demonstrated superiority over placebo in improving depressive symptoms and maintaining remission. (15)
Anxiety
Duloxetine is also FDA-approved for treating generalized anxiety disorder (GAD). Patients with GAD experience excessive and persistent worry that interferes with daily life. Additionally, they may experience the following physical symptoms:
- Restlessness
- Muscle tension
- Sleep disturbances
- Headaches
- Gastrointestinal symptoms
- Shortness of breath
- Heart palpitations and chest pain
- Fatigue
- Difficulty concentrating
A meta-analysis of eight randomized controlled trials found that duloxetine significantly improved symptoms of psychic anxiety, as measured by the Hamilton Anxiety Rating Scale (HAM-A), compared to placebo.
Another pooled analysis of three clinical trials showed that duloxetine-treated patients significantly improved HAM-A total scores and Sheehan Disability Scale (SDS) global functioning scores compared to placebo-treated patients.
Diabetic Neuropathy
Diabetic neuropathy is a type of nerve damage that can occur in patients with type 1 and type 2 diabetes mellitus, characterized by pain, tingling, and numbness, primarily in the extremities.
Clinical trials have demonstrated the efficacy of duloxetine in treating painful diabetic neuropathy (PDN), and the American Society of Pain and Neuroscience (ASPN) guidelines recommend duloxetine as a treatment option for PDN.
In a 12-week, multicenter, double-blind study, duloxetine dosed 60-120 mg daily improved the 24-hour average pain score compared to placebo, with effects observed as early as one week after randomization.
A systematic review and meta-analysis of randomized controlled trials further supported the efficacy of duloxetine, showing significant pain improvement and enhanced quality of life compared to placebo.
Fibromyalgia
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. It is often associated with other symptoms, such as irritable bowel syndrome, headaches, and mood disorders.
Duloxetine at doses of 60-120 mg per day has been shown to significantly reduce pain severity, improve quality of life, and alleviate depressive symptoms in patients with fibromyalgia (3, 31, 39).
Chronic Musculoskeletal Pain
The FDA has approved duloxetine for the treatment of chronic musculoskeletal pain. This approval is based on clinical trials demonstrating its efficacy in chronic low back pain and osteoarthritis. In these trials, duloxetine significantly reduced pain compared to placebo. (15, 33)
Off-Label Uses
Off-label drug use refers to the prescription of a medication for a purpose, patient population, dosage, or method of administration that the FDA has not officially approved.
Off-label use is a common and legal practice in medicine. Healthcare providers may prescribe medications off-label when clinical evidence or professional judgment supports their use in treating a condition not included in the FDA-approved labeling. (5)
Duloxetine is prescribed off-label for the following conditions:
- Chemotherapy-induced peripheral neuropathy (CIPN)
- Urinary incontinence
- Migraine prevention
Duloxetine Dosage and Administration
The typical starting dose for duloxetine is 30-60 mg daily, with adjustments based on efficacy and tolerability. Maintenance doses usually range between 60-120 mg daily. (13)
Gradual titration is recommended to minimize side effects. Starting at 30 mg for the first week before increasing to target doses can improve tolerability and reduce the risk of side effects. (13)
Abrupt discontinuation of duloxetine can cause withdrawal symptoms (15):
- Dizziness
- Nausea
- Vomiting
- Headache
- Paresthesia (tingling, burning, or prickly sensation)
- Fatigue
- Irritability
- Insomnia
- Anxiety
- Hyperhidrosis (excessive sweating)
If the decision has been made to discontinue duloxetine, its dose should be reduced gradually over several weeks. If a patient experiences intolerable symptoms with a dose reduction, they should resume the previous dose followed by smaller decreases. (13)
Duloxetine Side Effects
Using duloxetine may cause adverse side effects.
Common Side Effects
The most common side effects of duloxetine include:
- Nausea (23%)
- Headache (14%)
- Dry mouth (13%)
- Somnolence (10%),
- Fatigue (9%)
- Insomnia (9%)
- Constipation (9%)
- Diarrhea (9%)
- Dizziness (9%)
- Decreased appetite (7%)
- Hyperhidrosis (6%)
- Abdominal pain (5%)
These adverse effects are frequently observed during the first week of treatment but may resolve with time as the body adjusts to the medication. However, persistence and severity can vary among individuals, and some side effects may necessitate dose adjustments or discontinuation of the drug.
Serious Side Effects
Serious side effects associated with duloxetine include:
- Hepatotoxicity: Duloxetine has been associated with liver injury, particularly in patients with pre-existing liver conditions or those who consume excessive alcohol. Symptoms include jaundice, dark urine, abdominal pain, and elevated liver enzymes. Baseline and periodic liver function tests are recommended for at-risk populations.
- Orthostatic Hypotension and Syncope: In some cases, a significant drop in pressure upon standing, sometimes leading to fainting, has been reported. If persistent or severe, this may require a dose reduction or discontinuation of the medication.
- Serotonin Syndrome: A potentially life-threatening condition resulting from excessive serotonergic activity, often due to interactions with other serotonergic medications. Symptoms include agitation, confusion, rapid heart rate, hyperreflexia, and muscle rigidity. Serotonin syndrome requires immediate discontinuation of duloxetine and medical intervention.
- Severe Skin Reactions: Rare but serious reactions like erythema multiforme and Stevens-Johnson Syndrome (SJS) can occur, marked by severe rash and skin blistering. Duloxetine should be stopped immediately at the first sign of hypersensitivity.
- Increased Risk of Bleeding: Duloxetine can impair blood clotting, especially when taken with NSAIDs, aspirin, or anticoagulants, increasing the risk of bruising and bleeding.
- Mania or Hypomania: These mood states, characterized by elevated energy or irritability, may emerge in susceptible individuals. Screen for personal or family history of bipolar disorder before initiating treatment.
- Angle-Closure Glaucoma: This condition involves a sudden increase in eye pressure and can occur in patients with untreated narrow anterior eye angles.
- Seizures: Duloxetine can lower the seizure threshold. Use cautiously in patients with a history of seizure disorder.
- Hyponatremia: Cases of low sodium levels in the blood have been reported. In most cases, this occurs in association with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Black Box Warning
Duloxetine carries an FDA-mandated black box warning highlighting the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under the age of 25, particularly during the early phases of treatment or during dosage adjustments. While this risk is most significant in younger populations, all patients initiating duloxetine should be closely monitored for any signs of worsening depression, mood changes, or emergent suicidal ideation.
Drug Interactions
Using duloxetine with the following medications can increase the risk of adverse effects caused by drug interactions. Before taking duloxetine, tell your doctor about all prescription, over-the-counter, and other drugs or supplements you take to avoid potential interactions.
Using duloxetine with other drugs that also increase serotonin levels can raise your risk of serotonin syndrome:
- Buspirone
- Pain medications like fentanyl and tramadol
- Amphetamine/dextroamphetamine
- Lithium
- Monoamine oxidase inhibitors (MAOIs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants (TCAs)
- Triptans
- St. John's wort
- 5-hydroxytryptophan (5-HTP)
Drugs that inhibit the enzymes CYP1A2 and CYP2D6 can slow duloxetine metabolism, increasing its levels and the risk of side effects. Strong inhibitors of these enzymes should be avoided with duloxetine, including:
- Cimetidine
- Ciprofloxacin
- Fluvoxamine
- Fluoxetine
- Paroxetine
- Quinidine
Taking duloxetine with other medications that reduce the body's ability to clot increases the risk of bleeding:
- NSAIDs, such as aspirin, ibuprofen, and naproxen
- Anticoagulants, such as warfarin and rivaroxaban
Special Populations
Considerations should be made when deciding to use duloxetine in special populations.
Pregnancy and Lactation
Duloxetine is categorized as pregnancy category C, which means it has been shown to have adverse effects on embryo/fetal and postnatal development in animal reproduction studies.
Duloxetine use during pregnancy, particularly in the third trimester, may increase the risk of symptoms of poor neonatal adaptation, such as respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, and irritability. Data also suggest an increased risk of postpartum hemorrhage when used in the month before delivery. (13, 15)
Duloxetine is excreted in human milk, and there have been reports of sedation, poor feeding, and poor weight gain in breastfed infants. The benefits of breastfeeding should be weighed against the potential risks to the infant. (13, 15)
Geriatric Patients
The Beers Criteria, developed by the American Geriatrics Society, is a guideline identifying potentially inappropriate medications for older adults due to their higher susceptibility to adverse effects.
Duloxetine appears in the Beers Criteria primarily due to the increased risk of hyponatremia, orthostatic hypotension, and falls in elderly patients. Older adults are more prone to these side effects because of age-related declines in renal and hepatic function, which can impair drug clearance, and their heightened sensitivity to serotonergic and noradrenergic effects. (15)
Liver or Kidney Disease
Duloxetine should be avoided in patients with chronic liver disease or cirrhosis due to the increased risk of liver injury. It should be discontinued in patients who develop jaundice or other signs of significant liver dysfunction. (13)
For patients with mild to moderate renal impairment (creatinine clearance ≥30 mL/min), dose adjustments for duloxetine are not necessary. However, in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease, duloxetine exposure is significantly increased, and the risk of adverse effects is higher. Therefore, duloxetine is not recommended for these patients. (13)
Key Takeaways
- Duloxetine is a versatile medication effective in treating mental health and chronic pain conditions.
- While generally well-tolerated, it requires careful monitoring for side effects and interactions.
- Clinicians should adopt an individualized approach, considering patient-specific factors, and ensure open communication to optimize outcomes.
- Regular assessments and shared decision-making enhance efficacy and patient satisfaction, cementing duloxetine's role in comprehensive care.
%201.svg){kind=logo}
